2,819 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by Advisor OS LLC

Advisor OS LLC bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,819 shares of the biotechnology company’s stock, valued at approximately $431,000.

Several other institutional investors have also recently made changes to their positions in the business. Illinois Municipal Retirement Fund grew its position in shares of Biogen by 24.3% during the fourth quarter. Illinois Municipal Retirement Fund now owns 62,181 shares of the biotechnology company’s stock worth $9,509,000 after purchasing an additional 12,166 shares in the last quarter. Prasad Wealth Partners LLC purchased a new position in Biogen during the 4th quarter valued at approximately $222,000. BankPlus Trust Department purchased a new position in Biogen during the 4th quarter valued at approximately $106,000. Y Intercept Hong Kong Ltd grew its holdings in Biogen by 111.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 15,148 shares of the biotechnology company’s stock valued at $2,316,000 after buying an additional 7,970 shares in the last quarter. Finally, MONECO Advisors LLC purchased a new position in Biogen during the 4th quarter valued at approximately $205,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BIIB shares. Morgan Stanley cut their price target on Biogen from $192.00 to $157.00 and set an “equal weight” rating for the company in a report on Thursday, February 13th. StockNews.com cut Biogen from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 28th. Truist Financial cut their price target on Biogen from $220.00 to $210.00 and set a “buy” rating for the company in a report on Thursday, February 13th. HC Wainwright lowered their price objective on Biogen from $300.00 to $241.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein began coverage on Biogen in a research note on Tuesday, February 11th. They issued a “market perform” rating and a $160.00 price objective for the company. Seventeen investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Biogen has an average rating of “Hold” and a consensus target price of $213.33.

Biogen Trading Down 0.4 %

Shares of NASDAQ BIIB opened at $139.88 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The business has a fifty day simple moving average of $144.55 and a two-hundred day simple moving average of $169.15. The firm has a market cap of $20.47 billion, a PE ratio of 12.50, a price-to-earnings-growth ratio of 1.51 and a beta of -0.08. Biogen Inc. has a twelve month low of $128.51 and a twelve month high of $238.00.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. Analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.